We are live on ! Find out more
A

Abingworth Portfolio holdings

AUM $307M
1-Year Est. Return 93.47%
This Fund
S&P 500
This Quarter Est. Return
+40.84%
1 Year Est. Return
+93.47%
3 Year Est. Return
+184.38%
5 Year Est. Return
+342.7%
10 Year Est. Return
–
AUM
$175M
AUM Growth
+$14.2M
Cap. Flow
-$31.4M
Cap. Flow %
-17.91%
Top 10 Hldgs %
92.73%
Holding
17
New
1
Increased
2
Reduced
1
Closed
1

Top Buys

Rank Stock Value
1
SIEN
Sientra, Inc.
SIEN
+$4.46M
2
AVEO
AVEO Pharmaceuticals, Inc.
AVEO
+$948K
3
AUPH icon
Aurinia Pharmaceuticals
AUPH
+$827K

Top Sells

Rank Stock Value
1
CRSP icon
CRISPR Therapeutics
CRSP
+$37M
2
DERM
Dermira, Inc.
DERM
+$559K

Sector Composition

Rank Sector Weight
1 Healthcare 99.07%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CRSP icon
1
CRISPR Therapeutics
CRSP
$4.74B
$72.7M 41.53%
1,237,202
-650,000
-34% -$37M
SIEN
2
DELISTED
Sientra, Inc.
SIEN
$48.3M 27.6%
248,049
+28,148
+13% +$4.46M
PRTK
3
DELISTED
Paratek Pharmaceuticals, Inc.
PRTK
$10.6M 6.04%
1,041,131
– –
OBSV
4
DELISTED
ObsEva SA Ordinary Shares
OBSV
$6.66M 3.81%
440,000
– –
ONCT
5
DELISTED
Oncternal Therapeutics, Inc. Common Stock
ONCT
$5.2M 2.97%
2,423
– –
TARA icon
6
Protara Therapeutics
TARA
$230M
$4.84M 2.77%
50,447
– –
SRRA
7
DELISTED
Sierra Oncology, Inc. Common Stock
SRRA
$4.28M 2.44%
36,111
– –
CBAY
8
DELISTED
Cymabay Therapeutics
CBAY
$3.67M 2.09%
273,417
– –
CHMA
9
DELISTED
Chiasma, Inc. Common Stock
CHMA
$3.12M 1.78%
2,080,595
– –
ADAP
10
DELISTED
Adaptimmune Therapeutics
ADAP
$2.96M 1.69%
250,000
– –
RARE icon
11
Ultragenyx Pharmaceutical
RARE
$2.82B
$2.93M 1.67%
38,100
– –
CLLS
12
Cellectis
CLLS
$271M
$2.83M 1.61%
100,000
– –
AUPH icon
13
Aurinia Pharmaceuticals
AUPH
$2.01B
$2.25M 1.29%
400,434
+148,305
+59% +$827K
OCGN icon
14
Ocugen
OCGN
$440M
$2.2M 1.26%
14,815
– –
IMDZ
15
DELISTED
Immune Design Corp.
IMDZ
$1.62M 0.93%
352,300
– –
AVEO
16
DELISTED
AVEO Pharmaceuticals, Inc.
AVEO
$900K 0.51%
+40,000
New +$948K
DERM
17
DELISTED
Dermira, Inc.
DERM
– –
-70,000
Closed -$559K

Similar funds

AAM
Arabesque Asset Management London, United Kingdom $296M AUM 15.19% 1-Year Est. Return
EP
Equius Partners Novato, California $324M AUM 8.27% 1-Year Est. Return
LDFR
Lehman & Derafelo Financial Resources Media, Pennsylvania $337M AUM 8.16% 1-Year Est. Return
MPAM
Monarch Partners Asset Management Boston, Massachusetts $339M AUM 2.52% 1-Year Est. Return
MAG
Mass Ave Global New York $342M AUM 20.58% 1-Year Est. Return
CDIA
Capital Directions Investment Advisors Atlanta, Georgia $268M AUM 20.15% 1-Year Est. Return
GTCM
Gyon Technologies Capital Management Denville, New Jersey $267M AUM 11.62% 1-Year Est. Return
ACMV
August Capital Management VII Palo Alto, California $265M AUM 26.86% 1-Year Est. Return

Abingworth's Q2 2018 Portfolio in Review

As of Q2 2018, Abingworth held 17 positions worth $175M, up 8.8% from $161M the previous quarter. Its ten largest holdings account for 93% of the portfolio.

Abingworth withdrew a net $31.4M in Q2 2018, closing 1 position and reducing 1 holding. Its most notable exit was Dermira, Inc., an estimated $559K position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, up from 99% a quarter earlier.

Against the trend, Abingworth opened a new position in AVEO Pharmaceuticals, Inc. worth $900K.

  • Abingworth's largest Q2 2018 buy was AVEO Pharmaceuticals, Inc.: 40,000 shares worth $900K.
  • Abingworth added most to Sientra, Inc. in Q2 2018, an estimated $4.46M increase.
  • Abingworth's biggest Q2 2018 reduction was CRISPR Therapeutics, cutting an estimated $37M.
  • Abingworth fully exited Dermira, Inc. in Q2 2018, selling an estimated $559K.
  • Abingworth's ten largest holdings make up 93% of its $175M portfolio in Q2 2018.
  • Abingworth opened 1 new position and closed 1 in Q2 2018.
  • Abingworth's portfolio value rose 8.8% quarter-over-quarter to $175M.

Based on Abingworth's 13F filing for Q2 2018, filed 14 Aug 2018.